Wenqi (Wayne) Zeng MD, PhD

Wenqi (Wayne) Zeng MD, PhD has extensive work experience in the medical field. Wenqi (Wayne) has worked in various roles since 2000. In 2000, they were a Fellow of Clinical Molecular Genetics at the Massachusetts General Hospital. From 2005 to 2010, they were the Co-Director of Clinical Molecular Genetics at City of Hope. From 2010 to 2014, they were the Laboratory Director at Ambry Genetics. From 2014 to 2017, they were the Senior Director at Quest Diagnostics. From 2017 to 2020, they were the Co-founder & Senior VP at Apostle Inc and the CMO of Simcere Diagnostics. Since 2020, they have been the CLIA Lab Director at Apostle Diagnostics. At Apostle Inc, they have serviced public health and life science and guaranteed supply chain to help the community fight COVID-19. At Simcere Diagnostics, they have promoted strategic collaboration with Oxford Nanopore and Agena Bioscience and focused on liquid biopsy of cancer R&D. At Ambry Genetics, they have been involved in the first to offer exome services in 2011, the first to offer clinical hereditary cancer panels in 2012, and the first to offer BRCA-related testing panels after the Supreme Court decision in 2013. At City of Hope, they have developed molecular diagnostic testing for diffuse gastric cancer, VWF, breast cancer, and Colcon cancer, and reviewed genomics data and signed off clinical cases and results counseling. At Massachusetts General Hospital, they identified the mutations of SLC19A3 gene that causes biotin-responsive basal ganglia disease, one of the earliest cases of precision medicine.

Wenqi (Wayne) Zeng MD, PhD has an extensive education history. Wenqi (Wayne) obtained their Bachelor of Medicine, Neurology/Psychiatry Fellow (MD) from Central South University from 1984 to 1989. Wenqi (Wayne) then went on to pursue a Doctor of Philosophy (PhD) in Molecular Pathology and Molecular Genetics at the University of Otago from 1997 to 2001. Following their PhD, they completed a Postdoc Fellowship in Genomic Medicine, Molecular Neurogenetics, and Precision Medicine at Harvard Medical School - Massachusetts General Hospital from 2000 to 2005. Wenqi (Wayne) then completed a Fellowship of Clinical Molecular Genetics in Human/Medical Genetics, Clinical Molecular Genetics, and Medical Genomics at Harvard Medical School Postgraduate Medical Education from 2002 to 2005. Additionally, they have obtained certifications from the Center for Medicare and Medicaid Services, College of American Pathologists (CAP), California Department of Public Health, and American Board of Medical Genetics and Genomics.